Company / Working Capital
Vertex Pharmaceuticals Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$7.3B
FY2025
5-year range
$6.0B / $10.6B
FY2021-FY2025
Trend
+21.7%
vs FY2024
Sector context
#4 of 213
Health Care
What the data says
Among 213 Health Care companies, Vertex Pharmaceuticals is in the top 2% for working capital. Declined from $10.6B to $7.3B over the past 2 years.
Based on SEC 10-K filings.
$7.3B in FY2025 with a 5-year CAGR of +3.2%. Top quartile in the Health Care sector.
Declined from $10.6B to $7.3B over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -11.2%
- 5-Year CAGR
- +3.2%
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 213This company $7.3B Sector average $934.6M
▼
+685.3% above sector average
Key checks
Key Insights
- 5-year CAGR of +3.2%, indicating consistent growth.
- In FY2025, working capital increased 21.7% year-over-year.
- Ranks #4 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2023.
Company context
Key Data Points
- Strong profit margin: 31.4%
- Strong return on equity: 21.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.3B | +21.7% |
| FY2024 | $6.0B | -43.1% |
| FY2023 | $10.6B | +1.0% |
| FY2022 | $10.5B | +41.4% |
| FY2021 | $7.4B | +18.6% |
| FY2020 | $6.3B | +79.4% |
| FY2019 | $3.5B | +28.1% |
| FY2018 | $2.7B | +47.8% |
| FY2017 | $1.8B | +77.3% |
| FY2016 | $1.0B | +15.3% |
As of FY2025 · SEC 10-K · Updated Mar 17, 2026